CDKN2A/p14ARF Antibody (YA8565)

(Synonyms: ARF; CDK4I; CDKN2; CMM2; INK4; INK4A; MLM; MTS-1; MTS1; P14; P14ARF; P16; P16-INK4A; P16INK4)

CDKN2A/p14ARF Antibody (YA8565) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CDKN2A/p14ARF.

For research use only. We do not sell to patients.
  • Host:

    Mouse

  • Isotype:

    IgG1

  • Application:

    IHC-P, FC

  • Reactivity :

    Human

  • Formulation:

    Spplied in PBS (pH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.

  • Conjugation:
    Non-conjugated

Applications

Application
IHC-P Info
IHC-P: Immunohistochemistry-Paraffin
FC Info
FC: Flow Cytometry
Dilution Ratio 1:2000-2500 1:100

Product Details

Description

CDKN2A/p14ARF Antibody (YA8565) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CDKN2A/p14ARF.

  • Host Mouse
  • Clonality Monoclonal
  • Species Reactivity
    Human
  • Calculated Molecular Weight Predicted band size: 16.4 kDa
Immunogen

Full length human recombinant protein of human CDKN2A produced in E.coli.

Sensitivity

Endogenous

Purification

Affinity purified

Conjugation

Non-conjugated

Modification

Unmodified

Isotype

IgG1

Product Properties

  • Appearance

    Liquid

  • Formulation

    Spplied in PBS (pH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.

  • Storage & Stability

    Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

  • Shipping

    Shipping with blue ice.

Background

  • Function

    CDKN2A/p14ARF is capable of inducing cell cycle arrest in G1 and G2 phases. Acts as a tumor suppressor. Binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits the oncogenic action of MDM2 by blocking MDM2-induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis in a p53-independent manner by preventing the activation of cyclin B1/CDC2 complexes. Binds to BCL6 and down-regulates BCL6-induced transcriptional repression. Binds to E2F1 and MYC and blocks their transcriptional activator activity but has no effect on MYC transcriptional repression. Binds to TOP1/TOPOI and stimulates its activity. This complex binds to rRNA gene promoters and may play a role in rRNA transcription and/or maturation. Interacts with NPM1/B23 and promotes its polyubiquitination and degradation, thus inhibiting rRNA processing. Plays a role in inhibiting ribosome biogenesis, perhaps by binding to the nucleolar localization sequence of transcription termination factor TTF1, and thereby preventing nucleolar localization of TTF1. Interacts with COMMD1 and promotes its 'Lys63'-linked polyubiquitination. Interacts with UBE2I/UBC9 and enhances sumoylation of a number of its binding partners including MDM2 and E2F1. Binds to HUWE1 and represses its ubiquitin ligase activity. May play a role in controlling cell proliferation and apoptosis during mammary gland development|May be involved in regulation of autophagy and caspase-independent cell death; the short-lived mitochondrial isoform is stabilized by C1QBP

  • Subcellular Localization

    Nucleus, nucleolus,Nucleus, nucleoplasm,Mitochondrion

  • Isoforms & Post-Translational Modification

    Q8N726 has 6 isomers: Q8N726-1: 13903 Da (predicted); P42771-1: 16533 Da (predicted); P42771-2: 11215 Da (predicted); P42771-3: 12083 Da (predicted); P42771-4: 17883 Da (predicted); Q8N726-2: 8731 Da (predicted).
    Ubiquitinated in normal cells by TRIP12 via the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination at the N-terminus, regardless of the absence of lysine residues

  • Subunit

    Does not interact with cyclins, CDK1, CDK2, CDK4, CDK5 or CDK6

  • SwissProt ID

    Q8N726

  • Synonyms

    ARF; CDK4I; CDKN2; CMM2; INK4; INK4A; MLM; MTS-1; MTS1; P14; P14ARF; P16; P16-INK4A; P16INK4

CDKN2A/p14ARF Antibody (YA8565) Related Classifications

MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00